Stryker (SYK) Stock Forecast & Price Target

Stryker's recent financial reports indicate robust growth across several key product categories, with knee procedures seeing impressive increases of 7.6% in the U.S. and 8.8% internationally. The company achieved an operating margin of 30.2%, reflecting a Year-over-Year improvement driven by strong sales performance and significant growth in robotic-assisted procedures. Additionally, broad-based strength was observed across its business segments, culminating in organic sales growth of 11.0% for the quarter, underscoring the company's solid market position and positive operational momentum.

The analysis highlights a negative outlook for Stryker's stock primarily due to declining M&A contributions to revenue growth and lower projected organic growth rates, with expectations of slowing to 8% or less. Additionally, despite an improvement in the leverage ratio reflecting a stronger balance sheet, the company's leverage and M&A impact on top-line growth have fallen significantly below historical averages. Furthermore, anticipated headwinds from tariffs and stagnant gross margins, coupled with potential earnings dilution from acquisitions, further contribute to the concerns about Stryker's future financial performance.